{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:53:37Z","timestamp":1791104017831,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.eururo.2008.06.080","type":"journal-article","created":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T06:09:22Z","timestamp":1215670162000},"page":"740-764","source":"Crossref","is-referenced-by-count":225,"title":["A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder"],"prefix":"10.1016","volume":"54","author":[{"given":"Giacomo","family":"Novara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Galfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Secco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"D'Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cavalleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ficarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Artibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2008.06.080_bib1","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eursup.2006.09.001","article-title":"Advancing the management of overactive bladder: new data, new directions","volume":"6","author":"Chapple","year":"2007","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2008.06.080_bib3","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","article-title":"The current and future burden and cost of overactive bladder in five European countries","volume":"50","author":"Reeves","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib4","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.eururo.2006.11.040","article-title":"The economic costs of overactive bladder in Germany","volume":"51","author":"Klotz","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.eursup.2006.12.015","article-title":"Critical evaluation of the efficacy and safety of anticholinergics in overactive bladder","volume":"6","author":"Toozs-Hobson","year":"2007","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2008.06.080_bib6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eursup.2007.01.002","article-title":"Long-term management of overactive bladder with antimuscarinic agents","volume":"6","author":"Hampel","year":"2007","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2008.06.080_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2005.02.024","article-title":"The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib9","doi-asserted-by":"crossref","unstructured":"Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;18:CD003781.","DOI":"10.1002\/14651858.CD003781.pub2"},{"key":"10.1016\/j.eururo.2008.06.080_bib10","doi-asserted-by":"crossref","unstructured":"Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;3:CD005429.","DOI":"10.1002\/14651858.CD005429"},{"key":"10.1016\/j.eururo.2008.06.080_bib11","series-title":"Randomised controlled trials","author":"Jadad","year":"1998"},{"key":"10.1016\/j.eururo.2008.06.080_bib12","series-title":"Publication bias in meta-analysis: prevention, assessment and adjustment","author":"Rothstein","year":"2005"},{"key":"10.1016\/j.eururo.2008.06.080_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/(SICI)1520-6777(1997)16:6<533::AID-NAU3>3.0.CO;2-F","article-title":"Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients","volume":"16","author":"Nilsson","year":"1997","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2008.06.080_bib14","first-page":"718","article-title":"Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence","volume":"95","author":"Versi","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.eururo.2008.06.080_bib15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0149-2918(04)90174-9","article-title":"A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence","volume":"26","author":"Barkin","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.eururo.2008.06.080_bib16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1464-410X.2005.06031.x","article-title":"A double-blind randomized dose-response study comparing daily doses of 5mg, 10mg, and 15mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth","volume":"97","author":"Corcos","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000096338","article-title":"Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder","volume":"77","author":"J\u00fcnemann","year":"2006","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/BF02201987","article-title":"Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation","volume":"15","author":"Jonas","year":"1997","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1464-410x.1998.00501.x","article-title":"Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study","volume":"81","author":"Rentzhog","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0022-5347(05)68951-3","article-title":"Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity","volume":"161","author":"Millard","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0301-2115(00)00561-3","article-title":"Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder","volume":"98","author":"Jacquetin","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.eururo.2008.06.080_bib22","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1046\/j.1532-5415.2001.49144.x","article-title":"Tolterodine: a safe and effective treatment for older patients with overactive bladder","volume":"49","author":"Malone-Lee","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.eururo.2008.06.080_bib23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2008.06.080_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00192-002-1009-0","article-title":"A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder","volume":"14","author":"Swift","year":"2003","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.eururo.2008.06.080_bib25","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1742-1241.2006.01067.x","article-title":"Solifenacin significantly improves all symptoms of overactive bladder syndrome","volume":"60","author":"Chapple","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2008.06.080_bib28","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1464-410X.2005.05454.x","article-title":"A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder","volume":"95","author":"Chapple","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.eururo.2005.05.009","article-title":"Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist","volume":"48","author":"Foote","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00345-005-0507-3","article-title":"Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder","volume":"23","author":"Zinner","year":"2005","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00192-005-1340-3","article-title":"Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study","volume":"17","author":"Hill","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.eururo.2008.06.080_bib32","unstructured":"Nitti V, Wiatrak M, Kreitman L, Lipsitz D. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. ICS annual meeting; 2005. Abstract 306. Available at https:\/\/www.icsoffice.org\/publications\/2005\/PDF\/0306.PDF."},{"key":"10.1016\/j.eururo.2008.06.080_bib33","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","article-title":"Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib34","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.juro.2007.08.033","article-title":"Efficacy, safety, and tolerability of fesoterodine for overactive bladder syndrome","volume":"178","author":"Nitti","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib35","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","article-title":"Once-daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence","volume":"161","author":"Anderson","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2008.06.080_bib36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1464-410x.2000.00623.x","article-title":"A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10mg once daily) with conventional oxybutynin tablets (5mg twice daily) in patients whose symptoms were stabilized on 5mg twice daily of oxybutynin","volume":"85","author":"Birns","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib37","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1442-2042.2006.01387.x","article-title":"Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome","volume":"13","author":"Abrams","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib38","first-page":"351","article-title":"A randomized crossover trial comparing oxybutynin taken three times a day or taken \u201cwhen needed\u201d","volume":"13","author":"Burton","year":"1994","journal-title":"Neurourol Urod"},{"key":"10.1016\/j.eururo.2008.06.080_bib39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1185\/030079902125000570","article-title":"Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET)","volume":"18","author":"Sussman","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eururo.2008.06.080_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/00365599509180578","article-title":"Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study","volume":"29","author":"Mazur","year":"1995","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2008.06.080_bib41","unstructured":"Gittelman MC, Kaufman J. Solifenacin succinate 10mg once daily significantly improves symptoms of overactive bladder. Presented at the 17th International Federation of Gynecology and Obstetrics World Congress, Abstract 111. November 2\u20137, 2003; Santiago, Chile."},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2008.06.080_bib42","first-page":"94","article-title":"The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study","volume":"83","author":"Gittelman","year":"2003","journal-title":"Int J Gynaecol Obstetr"},{"key":"10.1016\/j.eururo.2008.06.080_bib43","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1464-410X.2006.06150.x","article-title":"Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence","volume":"97","author":"Staskin","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib44","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00192-005-0058-6","article-title":"Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin","volume":"17","author":"Cardozo","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.eururo.2008.06.080_bib45","first-page":"478","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder","volume":"16","author":"Van Kerrebroeck","year":"1997","journal-title":"Neurourol Urod"},{"key":"10.1016\/j.eururo.2008.06.080_bib46","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder","volume":"10","author":"Drutz","year":"1999","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.eururo.2008.06.080_bib48","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eururo.2008.06.080_bib49","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","article-title":"Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial","volume":"165","author":"Malone-Lee","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1442-2042.2002.00460.x","article-title":"Tolterodina: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder","volume":"90","author":"Lee","year":"2002","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib51","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eururo.2008.06.080_bib52","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1464-410X.2003.04468.x","article-title":"Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial","volume":"92","author":"Homma","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib53","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.eururo.2004.07.021","article-title":"Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity","volume":"46","author":"Giannitsas","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib54","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00345-004-0455-3","article-title":"Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial","volume":"22","author":"Homma","year":"2004","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib55","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1464-410x.1999.00251.x","article-title":"A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence","volume":"84","author":"Madersbacher","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib57","first-page":"488","article-title":"Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double blind, placebo-controlled, multicentre clinical trial","author":"Junemann","year":"2000","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.eururo.2008.06.080_bib58","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2005.04.023","article-title":"Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder","volume":"48","author":"J\u00fcnemann","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib59","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib60","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.eururo.2007.05.027","article-title":"Treatment outcomes in the STAR study: a subanalysis of solifenacin 5mg and tolterodine ER 4mg","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib61","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-5347(17)38459-8","article-title":"Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo","volume":"145","author":"Th\u00fcroff","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib62","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1464-410X.2002.02905.x","article-title":"A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder","volume":"90","author":"Leung","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.06.080_bib63","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2125.2005.02356.x","article-title":"Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial","volume":"59","author":"Altan-Yaycioglu","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eururo.2008.06.080_bib64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(05)66095-8","article-title":"A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence","volume":"166","author":"Davila","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2008.06.080_bib66","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2006.11.033","article-title":"Transdermal oxybutynin: sticking to the facts","volume":"51","author":"Cartwright","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib67","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.eururo.2007.03.070","article-title":"Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials","volume":"52","author":"Colli","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.06.080_bib68","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/0895-4356(91)90160-B","article-title":"Validation of an index of the quality of review articles","volume":"44","author":"Oxman","year":"1991","journal-title":"J Clin Epidemiol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808008026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808008026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T19:35:34Z","timestamp":1588793734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283808008026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0302283808008026"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2008.06.080","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}